Tumor growth enhances cross-presentation leading to limited T cell activation without tolerance

Journal of Experimental Medicine

Volumn 195, Issue 4, 2002, Pages 423-435

  Nguyen, Linh T ^a   Elford, Alisha R ^a   Murakami, Kiichi ^a   Garza, Kristine M ^b   Schoenberger, Stephen P ^c   Odermatt, Bernhard ^d   Speiser, Daniel E ^e   Ohashi, Pamela S ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TEXAS AT EL PASO   (United States)

^c LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e LUDWIG INSTITUTE FOR CANCER RESEARCH   (Switzerland)

Author keywords

CD40; Cytotoxic T lymphocytes; Immune tolerance; Immunotherapy; Neoplasms

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CYTOTOXIC T LYMPHOCYTE; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; INSULINOMA; LYMPHOCYTE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH;

ADOPTIVE TRANSFER; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGEN PRESENTATION; ANTIGENS, CD40; ANTIGENS, CD44; ANTIGENS, NEOPLASM; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; CELL DIVISION; FLOW CYTOMETRY; HYPOGLYCEMIA; IMMUNE TOLERANCE; IMMUNOLOGIC SURVEILLANCE; IMMUNOTHERAPY, ACTIVE; INSULINOMA; LYMPH NODES; LYMPHOCYTE ACTIVATION; MICE; MICE, TRANSGENIC; RADIATION CHIMERA; SURVIVAL ANALYSIS; T-LYMPHOCYTES, CYTOTOXIC; TIME FACTORS;

EID: 0037128173     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.20010032     Document Type: Article

References (85)

1. Genes coding for tumor antigens recognized by cytolytic T lymphocytes
2. The makings of a tumor rejection antigen
3. A new era for cancer immunotherapy based on the genes that encode cancer antigens
4. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice
5. T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors
6. Decreased expression of the signaltransducing ζ chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma
7. Timely immunization subverts the development of peripheral nonresponsiveness and suppresses tumor development in simian virus 40 tumor antigen-transgenic mice
8. Variable expression of CD3-ζ chain in tumor-infiltrating lymphocytes (TIL) derived from renal-cell carcinoma: Relationship with TIL phenotype and function
9. + T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma
10. Pre-B acute lymphoblastic leukemia cells may induce T-cell anergy to alloantigen
11. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression
12. Tumor antigens are constitutively presented in the draining lymph nodes
13. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
14. Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: Implications for tumor immunotherapy
15. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction
16. Tolerance and cancer: A critical issue in tumor immunology
17. Costimulation of T lymphocytes: The role of CD28, CTLA-4 and B7/BB1 in interleukin-2 production and immunotherapy
18. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens
19. Cross-presentation: A general mechanism for CTL immunity and tolerance
20. Major histocompatibility complex class I-restricted cross-presentation is biased towards high dose antigens and those released during cellular destruction
21. CD8 T cell ignorance or tolerance to islet antigens depends on antigen dose
22. + T cell tolerance to peripherally expressed antigens
23. Cross-presentation of tumour antigens: Evaluation of threshold, duration, distribution and regulation
24. + T cells
25. + T cell tolerance to parenchymal self-antigens requires presentation by bone marrow-derived antigen-presenting cells
26. Heritable formation of pancreatic β-cell turnouts in transgenic mice expressing recombinant insulin/ simian virus 40 oncogenes
27. Interactions between SV40 large-tumor antigen and the growth suppressor proteins pRB and p53
28. Cell and molecular biology of simian virus 40: Implications for human infections and disease
29. T-cell tolerance toward a transgenic β-cell antigen and transcription of endogenous pancreatic genes in thymus
30. Pancreatic gene expression in rare cells of thymic medulla: Evidence for functional contribution to T cell tolerance
31. Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice
32. Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: Implications for immunotherapy
33. Tolerance induction in double specific T-cell receptor transgenic mice varies with antigen
34. Enhanced positive selection of a transgenic TCR by a restriction element that does not permit negative selection
35. Mature T cell reactivity altered by a peptide agonist that induces positive selection
36. The SCID but not the RAG-2 gene product is required for Sμ-Sε heavy chain class switching
37. Anti-viral protection and prevention of lymphocytic choriomeningitis or of the local footpad swelling reaction in mice by immunization with vaccinia-recombinant virus expressing LCMVWE nucleoprotein or glycoprotein
38. Tolerance is overcome in beef insulin-transgenic mice by activation of low-avidity autoreactive T cells
39. Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity
40. Tumor immunology
41. The risk of autoimmunity associated with tumor immunotherapy
42. Detection of antigen-specific T cells with multivalent soluble class II MHC covalent peptide complexes
43. T cell tolerance based on avidity thresholds rather than complete deletion allows maintenance of maximal repertoire diversity
44. b mutants are generated by genetic micro-recombination (gene conversion) events
45. Extrathymic tolerance of mature T cells: Clonal elimination as a consequence of immunity
46. T cell immunity after a viral infection versus T cell tolerance induced by soluble viral peptides
47. Role of antigen, CD8, and cytotoxic T lymphocyte (CTL) avidity in high dose antigen induction of apoptosis of effector CTL
48. A cell culture model for T lymphocyte clonal anergy
49. Functional maturation of an antiviral cytotoxic T-cell response
50. Role of antigen-presenting cells in mediating tolerance and autoimmunity
51. Induction of diabetes is influenced by the infectious virus and local expression of MHC class I and TNF-α
52. + T cells specific for a pancreatic β cell neo-antigen
53. Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy
54. Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo
55. Antigen expressed on tumor cells fails to elicit an immune response, even in the presence of increased numbers of tumor-specific cytotoxic T lymphocyte precursors
56. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytotoxic T lymphocytes
57. Immune surveillance against a solid tumor fails because of immunological ignorance
58. Immunological ignorance of silent antigens as an explanation of tumor evasion
59. + T cells following vaccination with antigenic peptide
60. Peptide-induced T-cell tolerance to prevent autoimmune diabetes in a transgenic mouse model
61. Dendritic cells and the control of immunity
62. Role of antigen presenting cells in mediating tolerance and autoimmunity
63. + cytotoxic T lymphocyte priming capacity upon activation by T helper cell-independent or -dependent stimuli
64. Cross-presentation, dendritic cells, tolerance and immunity
65. Longevity of antigen presentation and activation status of APC are decisive factors in the balance between CTL immunity versus tolerance
66. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo
67. Loss of T-cell receptor ζ chain and p56-ck in T-cells infiltrating human renal cell carcinoma
68. Lymphocyte-mediated immunosurveillance of epithelial cancers?
69. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
70. Dendritic cells as adjuvants for immune-mediated resistance to tumors
71. Dendritic cell vaccines for cancer immunotherapy
72. The dendritic cell and human cancer vaccines
73. Immunobiology of dendritic cells
74. Activation of human dendritic cells through CD40 crosslinking
75. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation
76. High level IL-12 production by murine dendritic cells: Upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10
77. CD40 and CD154 in cell-mediated immunity
78. CD40 ligand induces an antileukemia immune response in vivo
79. Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells
80. CD40 ligand/trimer DNA enhances both humoral and cellular immune responses and induces protective immunity to infectious and tumor challenge
81. Cutting edge: Dendritic cells require maturation via CD40 to generate protective antitumor immunity
82. Antitumor effect of CD40 ligand: Elicitation of local and systemic antitumor responses by IL-12 and B7
83. Synergistic action of fms-like tyrosine kinase 3 ligand and CD40 ligand in the induction of dendritic cells and generation of antitumor imunity in vivo
84. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy
85. + T-cell tolerance to T-cell priming through in vivo ligation of CD40